CRP and interstitial lung disease: As for the poor prognostic factors for ICI-induced ILD (ICI-ILD), a study on nivolumab in NSCLC identified a diffuse alveolar damage-like radiographic pattern, onset of ILD ≤ 60 days from the initial dose of nivolumab, pleural effusion present before nivolumab treatment, abnormal opacities distributed contralateral to the tumor or bilaterally, and abnormal changes in C-reactive protein (CRP) levels [3].